Radioembolization for Primary and Metastatic Liver Cancer

Khairuddin Memon, Robert J. Lewandowski, Laura Kulik, Ahsun Riaz, Mary F. Mulcahy, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

The incidence of hepatocellular carcinoma is increasing. Most patients present beyond potentially curative options and are usually affected by underlying cirrhosis. In this scenario, transarterial therapies, such as radioembolization, are rapidly gaining acceptance as a potential therapy for hepatocellular carcinoma and liver metastases. Radioembolization is a catheter-based liver-directed therapy that involves the injection of micron-sized embolic particles loaded with a radioisotope by use of percutaneous transarterial techniques. Cancer cells are preferentially supplied by arterial blood and normal hepatocytes by portal venous blood; therefore, radioembolization specifically targets tumor cells with a high dose of lethal radiation and spares healthy hepatocytes. The antitumor effect mostly comes from radiation rather than embolization. The most commonly used radioisotope is yttrium-90. The commercially available devices are TheraSphere (glass based; MDS Nordion, Ottawa, Canada) and SIR-Sphere (resin based; Sirtex, Lane Cove, Australia). The procedure is performed on an outpatient basis. The incidence of complications is comparatively less than other locoregional therapies and may include nausea, fatigue, abdominal pain, hepatic dysfunction, biliary injury, fibrosis, radiation pneumonitis, gastrointestinal ulcers, and vascular injury. However, these complications can be avoided by meticulous pretreatment assessment, careful patient selection, and adequate dosimetry. This article focuses on both the technical and clinical aspects of radioembolization with emphasis on patient selection, uses and complications.

Original languageEnglish (US)
Pages (from-to)294-302
Number of pages9
JournalSeminars in Radiation Oncology
Volume21
Issue number4
DOIs
StatePublished - Oct 1 2011

Fingerprint

Liver Neoplasms
Yttrium Radioisotopes
Patient Selection
Hepatocytes
Hepatocellular Carcinoma
Liver
Fibrosis
Radiation
Radiation Pneumonitis
Vascular System Injuries
Incidence
Therapeutics
Radioisotopes
Nausea
Abdominal Pain
Ulcer
Canada
Fatigue
Glass
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{7113a3c66f2248a28448e6e3e1e0bdc6,
title = "Radioembolization for Primary and Metastatic Liver Cancer",
abstract = "The incidence of hepatocellular carcinoma is increasing. Most patients present beyond potentially curative options and are usually affected by underlying cirrhosis. In this scenario, transarterial therapies, such as radioembolization, are rapidly gaining acceptance as a potential therapy for hepatocellular carcinoma and liver metastases. Radioembolization is a catheter-based liver-directed therapy that involves the injection of micron-sized embolic particles loaded with a radioisotope by use of percutaneous transarterial techniques. Cancer cells are preferentially supplied by arterial blood and normal hepatocytes by portal venous blood; therefore, radioembolization specifically targets tumor cells with a high dose of lethal radiation and spares healthy hepatocytes. The antitumor effect mostly comes from radiation rather than embolization. The most commonly used radioisotope is yttrium-90. The commercially available devices are TheraSphere (glass based; MDS Nordion, Ottawa, Canada) and SIR-Sphere (resin based; Sirtex, Lane Cove, Australia). The procedure is performed on an outpatient basis. The incidence of complications is comparatively less than other locoregional therapies and may include nausea, fatigue, abdominal pain, hepatic dysfunction, biliary injury, fibrosis, radiation pneumonitis, gastrointestinal ulcers, and vascular injury. However, these complications can be avoided by meticulous pretreatment assessment, careful patient selection, and adequate dosimetry. This article focuses on both the technical and clinical aspects of radioembolization with emphasis on patient selection, uses and complications.",
author = "Khairuddin Memon and Lewandowski, {Robert J.} and Laura Kulik and Ahsun Riaz and Mulcahy, {Mary F.} and Riad Salem",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.semradonc.2011.05.004",
language = "English (US)",
volume = "21",
pages = "294--302",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Radioembolization for Primary and Metastatic Liver Cancer. / Memon, Khairuddin; Lewandowski, Robert J.; Kulik, Laura; Riaz, Ahsun; Mulcahy, Mary F.; Salem, Riad.

In: Seminars in Radiation Oncology, Vol. 21, No. 4, 01.10.2011, p. 294-302.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Radioembolization for Primary and Metastatic Liver Cancer

AU - Memon, Khairuddin

AU - Lewandowski, Robert J.

AU - Kulik, Laura

AU - Riaz, Ahsun

AU - Mulcahy, Mary F.

AU - Salem, Riad

PY - 2011/10/1

Y1 - 2011/10/1

N2 - The incidence of hepatocellular carcinoma is increasing. Most patients present beyond potentially curative options and are usually affected by underlying cirrhosis. In this scenario, transarterial therapies, such as radioembolization, are rapidly gaining acceptance as a potential therapy for hepatocellular carcinoma and liver metastases. Radioembolization is a catheter-based liver-directed therapy that involves the injection of micron-sized embolic particles loaded with a radioisotope by use of percutaneous transarterial techniques. Cancer cells are preferentially supplied by arterial blood and normal hepatocytes by portal venous blood; therefore, radioembolization specifically targets tumor cells with a high dose of lethal radiation and spares healthy hepatocytes. The antitumor effect mostly comes from radiation rather than embolization. The most commonly used radioisotope is yttrium-90. The commercially available devices are TheraSphere (glass based; MDS Nordion, Ottawa, Canada) and SIR-Sphere (resin based; Sirtex, Lane Cove, Australia). The procedure is performed on an outpatient basis. The incidence of complications is comparatively less than other locoregional therapies and may include nausea, fatigue, abdominal pain, hepatic dysfunction, biliary injury, fibrosis, radiation pneumonitis, gastrointestinal ulcers, and vascular injury. However, these complications can be avoided by meticulous pretreatment assessment, careful patient selection, and adequate dosimetry. This article focuses on both the technical and clinical aspects of radioembolization with emphasis on patient selection, uses and complications.

AB - The incidence of hepatocellular carcinoma is increasing. Most patients present beyond potentially curative options and are usually affected by underlying cirrhosis. In this scenario, transarterial therapies, such as radioembolization, are rapidly gaining acceptance as a potential therapy for hepatocellular carcinoma and liver metastases. Radioembolization is a catheter-based liver-directed therapy that involves the injection of micron-sized embolic particles loaded with a radioisotope by use of percutaneous transarterial techniques. Cancer cells are preferentially supplied by arterial blood and normal hepatocytes by portal venous blood; therefore, radioembolization specifically targets tumor cells with a high dose of lethal radiation and spares healthy hepatocytes. The antitumor effect mostly comes from radiation rather than embolization. The most commonly used radioisotope is yttrium-90. The commercially available devices are TheraSphere (glass based; MDS Nordion, Ottawa, Canada) and SIR-Sphere (resin based; Sirtex, Lane Cove, Australia). The procedure is performed on an outpatient basis. The incidence of complications is comparatively less than other locoregional therapies and may include nausea, fatigue, abdominal pain, hepatic dysfunction, biliary injury, fibrosis, radiation pneumonitis, gastrointestinal ulcers, and vascular injury. However, these complications can be avoided by meticulous pretreatment assessment, careful patient selection, and adequate dosimetry. This article focuses on both the technical and clinical aspects of radioembolization with emphasis on patient selection, uses and complications.

UR - http://www.scopus.com/inward/record.url?scp=80052988674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052988674&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2011.05.004

DO - 10.1016/j.semradonc.2011.05.004

M3 - Review article

C2 - 21939859

AN - SCOPUS:80052988674

VL - 21

SP - 294

EP - 302

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 4

ER -